Molecular genetic studies have pointed to a relationship between congenital lipodystrophies and some cardiac disorders. For instance, mutations in LMNA, which encodes nuclear lamin A and C isoforms, cause autosomal dominant (AD) Dunnigantype familial partial lipodystrophy (FPLD; MIM 151660) (1) , and also AD Emery-Dreifuss muscular dystrophy (EMD2; MIM 181350), which can occur with a cardiac conduction abnormalities, such as complete atrio-ventricular block (2) , AD dilated cardiomyopathy (CMD1A; MIM 115200) (3) and AD limb girdle muscular dystrophy, with cardiac conduction abnormalities (LGMD1B; MIM 159001) (4) . The pleiotropic effects of mutant LMNA link these disorders, but there is typically little overlap between their clinical features. FPLD is characterized by regional wasting of adipose tissue, but not by cardiomyopathy or cardiac conduction defects (5) . Similarly, EMD2, CMD1A and LGMD1B are not characterized by abnormalities 283 in adipose tissue. However, the associated metabolic disturbances in FPLD, such as insulin resistance, dyslipidemia and diabetes, indirectly lead to premature coronary atherosclerosis (6) . The mechanisms by which mutant LMNA produces FPLD or the cardiac abnormalities in EMD2, CMD1A or LGMD1B are unknown. Similarly, the possible relationship between cardiac abnormalities and other genetic forms of lipodystrophy is incompletely understood.
Berardinelli-Seip congenital complete lipodystrophy (BSCL) is a rare autosomal recessive (AR) disorder characterized by severe insulin resistance, lack of subcutaneous fat and muscular hypertrophy (7) (8) (9) (10) . Other features include acanthosis nigricans, accelerated growth, hepatosplenomegaly, hypertriglyceridemia and hyperinsulinemia (7) (8) (9) (10) . There are at least two BSCL loci: BSCL1 on chromosome 9q34 (11) and BSCL2 on chromosome 11q13 (12) . Mutational analysis in BSCL subjects has shown that BSCL2 is a gene that encodes a G-protein-like molecule called 'seipin' (12) . The present authors describe a subject with BSCL who is homozygous for a nonsense mutation in BCSL2 and had symmetrical hypertrophic cardiomyopathy beginning at a very young age.
Case report
The patient is currently 10 years old. Her parents were not known to be consanguineous, although they came from the same region of Portugal. She was born after an uncomplicated full-term pregnancy and weighed 2950 g at birth. At 2 weeks, the subject was admitted to hospital with failure to thrive. She had hepatomegaly, a prominent jaw and hirsutism. Laboratory investigations showed elevations in serum glucose, ammonium, uric acid and triglycerides. Based on a liver biopsy, a diagnosis of type 1A glycogen storage disease was considered, but not confirmed on enzyme analysis. Over the first year of life, the subject had accelerated growth. Her weight, length and head circumference at 3 months of age were above the fiftieth, ninety-fifth and seventy-fifth percentiles, respectively. At one year of age, these measurements exceeded the ninety-seventh percentile, and her bone age was 18 months, without any lytic lesions. Computerized tomography and magnetic resonance imaging of the head were normal at 18 months. The subject's accelerated growth continued, and by 23 months of age, her height was 98 cm (fiftieth percentile for 3.5 years), her weight was 18 kg (fiftieth percentile for 5 years) and her head circumference was 52 cm (fiftieth percentile for 10 years).
At 2 years of age, the subject had coarse facial features, with hollowed cheeks, a triangular chin and a progeroid appearance (Fig. 1A) . She continued to have hirsutism, with excessive hair growth on her back, shoulders and face. She had clitoromegaly and Tanner stage 2 breast development. The subject also had hepatomegaly and splenomegaly, with an umbilical hernia. Neurological examination was normal. She had marked muscular hypertrophy, most notably affecting her arms and calves. The subject also had absence of all subcutaneous fat, enlarged hands and feet, and acanthosis nigricans particularly involving the skin on her neck, elbows, knees, periumbilical region, axillae and groin (Fig. 1B) . The clinical diagnosis of BSCL was then made.
The subject's biochemical evaluations typically showed dyslipidemia and hyperinsulinemia. At 3 months of age, total cholesterol (TC) and triglycerides (TGs) were 2.78 and 6.02 mmol L ª1 , respectively. At 3 years, her fasting glucose and serum insulin were 5.1 mmol L ª1 and 554 pmol L ª1 (normal
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upper limit Ω 175 pmol L ª1 ), respectively. She had a voracious appetite until 6 years of age, with no polydipsia or polyuria. At 7 years, because of persistent elevations in postprandial glucose, glycosylated haemoglobin and insulin, oral metformin was initiated. This has been tolerated well over the past 3 years. The subject currently takes metformin three times daily (1000, 500 and 1000 mg) and her current glycosylated haemoglobin is 8.3% (normal upper limit Ω 6.5%). Abdominal ultrasound performed at 10 years of age showed hepatic steatosis with hepatosplenomegaly (liver span Ω 19 cm). Both kidneys were enlarged (right and left renal spans of 15 and 14.2 cm, respectively). Serum transaminases were mildly elevated and urinalysis was normal. Tests of thyroid function, and corticosteroid and sex steroid metabolism were always normal.
Myocardial hypertrophy was present from a very young age. At 6 months, a grade 3/6 apical systolic ejection murmur was noted with cardiomegaly on chest X-ray, and evidence for ventricular hypertrophy was obtained on both electrocardiogram (EKG) and two-dimensional (2D) echocardiogram. At 3 years of age, a 2D echocardiogram showed concentric hypertrophy of the left ventricle, moderate hypertrophy of the right ventricle, increased intraventricular septal thickness, good myocardial contractility and no evidence of outflow obstruction. Results of serial 2D echocardiograms are shown in Fig. 2 . At all times, the thickness of such structures as the intraventricular septum and the left ventricle posterior wall were two to three times greater than age-specific population means, and were always well in excess of the ninety-fifth percentile for age (Fig. 2) . At 5 years, the subject began to experience mild exercise intolerance with occasional palpitations. Ventricular hypertrophy on 2D echocardiography was unchanged, but there was a decline in the shortening fraction to 28%. Twenty-four-hour continuous Holter monitoring was normal. At 8 years of age, she had reduced exercise tolerance, experiencing fatigue and shortness of breath with minimal exercise. Subsequent echocardiography showed persistent left ventricular hypertrophy with no significant change in function (Fig. 3) . At 10 years, the patient 
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had dyspnoea with minimal exertion. The most recent EKG showed voltage criteria for left ventricular hypertrophy and a 2D echocardiogram confirmed concentric ventricular hypertrophy with a gradient across the left ventricular outflow tract.
Mutation analysis showed that the patient was homozygous for an insertion of a single adenosine residue in codon 699, which shifted the reading frame and resulted in premature truncation of the BCSL2 gene product. This mutation had been previously reported among subjects with BSCL from South Africa of Portuguese descent (12) .
The subject's family history is positive for BSCL on both sides of the family. Her father had two affected male cousins who were born to consanguineous parents and died in childhood. Another affected female first cousin to the father died at 30 years of age with renal failure. An affected male, her mother's second cousin, died at 28 years of age.
Discussion
The present authors describe a patient with typical BCSL as a result of homozygosity for mutant BSCL2 who also had cardiomyopathic changes which were detected non-invasively from the first year of life and followed up for 10 years. These findings show that mutant BSCL2 in complete lipodystrophy can be associated with cardiac abnormalities beginning very early in life. There have been a few reports of cardiac abnormalities in congenital complete lipodystrophy, but none has had molecular analysis (13) (14) (15) (16) (17) (18) (19) . Thus, it is not clear whether other subjects with congenital complete lipodystrophy and cardiac abnormalities have mutations in BSCL1, BCSL2 or some other uncharacterized loci.
Hypertrophic cardiomyopathy in BSCL patients is usually reported as being symmetrical; however, there have been reports of asymmetrical hypertrophy (ASH) (15, 17) . The present subject transiently met the criteria for ASH at 2 years of age, but had symmetric hypertrophy consistently thereafter. Such asymmetry may be a context-dependent exaggeration of normal development in the presence of hyperinsulinaemia, since normally developing human hearts have disproportionate thickening of the interventricular septum (20, 21) . Other patients with congenital complete lipodystrophy had normal systolic function with prominence of diastolic dysfunction (16) (17) (18) (19) . In addition, there have been reports of associated aortic outflow tract obstruction (15) . Long-term follow-up studies have suggested that cardiac involvement in BSCL might be predictive of a poor prognosis, with three out of seven patients dying before the fourth decade of life (16) . The present subject had developed symptoms and signs of trivial left ventricular outflow tract obstruction at 9 years of age while maintaining normal contractility. The prognostic significance of this is unclear.
Autopsies of patients with BSCL have shown myocyte hypertrophy without evidence of myocyte rearrangement, fatty infiltration or glycogen storage, which contrasts with the findings in typical hypertrophic cardiomyopathy (16, 18) . It should be noted that some autopsy reports of patients with BSCL have shown no evidence of any gross or microscopic hypertrophy (22, 23) . There has also been inconsistent evidence of sub-endocardial collagen deposits, diffuse interstitial collagen deposits and intramural coronary artery intimal fibrosis (14, 16) . Knowledge of the molecular basis of one form of BSCL might permit the stratification of affected subjects. Genotype-phenotype correlation analysis may help to begin to unravel the cellular mechanisms underlying the apparent heterogeneity of the cardiac involvement in BSCL.
The LMNA-related diseases indicate that mutations in one gene can cause both lipodystrophy and cardiomyopathy, although typically not simultaneously in the same patient (5) . Thus, the simultaneous occurrence of lipodystrophy and cardiomyopathy in the present subject could represent pleiotropic effects of the same gene mutation on cellular growth, differentiation and development. Alternatively, severe insulin resistance at a very young age may provide the context for the development of the hypertrophic cardiomyopathy in BCSL. In some 286 insulin-resistant states, there are apparent crossover effects between insulin and type 1 insulin-like growth factor (IGF-1). This phenomenon has been called 'specificity spillover', in which cellular receptors may be activated by heterogeneous, non-homologous hormones (17, (24) (25) (26) . Specifically, IGF-1 receptors mediate cellular growth and differentiation, bind insulin at high concentrations, and stimulate cell growth in vitro (27) . Myocardial tissue contains high concentrations of IGF-1 receptors: the frequent occurrence of hypertrophic cardiomyopathy in hyperinsulinaemic states, such as among infants of diabetic mothers (20) , nesidioblastosis (20) , Beckwith-Wiedemann syndrome (28), leprechaunism (27) and perhaps BSCL, may be the result of insulin action on cardiac IGF-1 receptors. The similarity of effects of insulin and IGF-1 has been used therapeutically, such as IGF-1 administration to ameliorate the hyperglycaemia in insulin resistance (29, 30) .
In summary, the present authors have reported that a patient with BSCL caused by homozygosity for a nonsense mutation in BSCL2 has hypertrophic cardiomyopathy that began in infancy. The findings confirm that this form of congenital complete lipodystrophy can present with very early cardiac findings. The mechanistic basis for the hypertrophic cardiomyopathy is unclear: it may either be primarily caused by a direct effect of the mutant gene or it might be secondary to the context of hyperinsulinaemia, which might in turn affect cardiac development. The variability of the association and severity of cardiomyopathy in patients with complete generalized lipodystrophy may be a result of the differential effects of various mutations in the same gene, or of mutations in different genes which underlie the BSCL phenotype.
